Verastem (VSTM)
(Delayed Data from NSDQ)
$2.74 USD
-0.20 (-6.80%)
Updated Jul 5, 2024 04:00 PM ET
After-Market: $2.73 -0.01 (-0.36%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth C Momentum F VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
VSTM 2.74 -0.20(-6.80%)
Will VSTM be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for VSTM based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for VSTM
Verastem (VSTM) Up on Upbeat Early Pancreatic Cancer Study Data
Verastem (VSTM) Up 8% on Fast Track Tag for NSCLC Combo Therapy
VSTM: What are Zacks experts saying now?
Zacks Private Portfolio Services
All You Need to Know About Verastem (VSTM) Rating Upgrade to Buy
Novo Nordisk (NVO) to Report Q2 Earnings: What's in the Cards?
Verastem (VSTM) Upgraded to Strong Buy: What Does It Mean for the Stock?
Other News for VSTM
Verastem Updates Corporate Presentation with Latest Insights
GenFleet Receives IND Approval from China's NMPA for GFH375, an Oral KRAS G12D (ON/OFF) Inhibitor, in a Phase I/II Clinical Trial Treating Advanced Solid Tumor Patients with KRAS G12D Mutation
Verastem partner GenFleet says China's NMPA approved clinical trial application
Pancreatic Cancer on the Rise: How Biotech Firms are Developing Groundbreaking Treatments
Verastem: Market Overreaction Creates A Dip Buying Opportunity